Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
Funding Rounds (2) - $4.49MUpdate
Current Team (1)Update
|Dec 19, 2011||FinSMEs - FinSMEs|
Belfield Innovation Park
Dublin, Dublin 4